Used in research and development for targeting IgE-expressing B cells, this antibody shows potential in treating allergic diseases by reducing the production of immunoglobulin E (IgE). It is investigated for conditions such as asthma, allergic rhinitis, and atopic dermatitis where IgE plays a central role in triggering allergic responses. By selectively binding to membrane-bound IgE on B cells, it may lead to long-term suppression of allergic reactions, offering a novel approach to allergy treatment beyond symptom management.